<DOC>
	<DOCNO>NCT01441401</DOCNO>
	<brief_summary>This investigation aim understand follow issue pediatric patient , well assess need special investigation post-marketing clinical study : - The frequency treatment related adverse event . - The frequency efficacy assessment . - Treatment related unlisted adverse event Japanese Package Insert . - Risk factor likely affect frequency treatment related adverse event .</brief_summary>
	<brief_title>Safety Efficacy Gabapen Pediatric ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All patient investigator prescribes first gabapentin register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>All pediatric subject ( age 315 year ) investigator prescribe first gabapentin ( tablet , syrup , switch syrup tablet ) register consecutively number subject reach target number order extract patient enrol investigation random . Patients enrol drug use investigation Gabapen tablet adult ( protocol No . A9451163 ) . Patients receive Gabapen tablet syrup , except switch tablet syrup .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Gabapentin</keyword>
	<keyword>Epilepsies</keyword>
	<keyword>safety</keyword>
</DOC>